Merck to acquire Pappas Capital portfolio company VelosBio in USD2.75bn deal
Pappas Capital’s portfolio company, VelosBio Inc (VelosBio), is to be acquired by a subsidiary of Merck for USD2.75 billion in cash, subject to customary adjustments. The exit is amongst Pappas Capital’s most successful in its 25-plus-year history. VelosBio is a clinical-stage biopharmaceutical company committed to developing first-in-class cancer therapies targeting
